Transvaginal mesh sling shows good short-term results

San Diego--The transvaginal permanent mesh sling provides a safe option with excellent early results for more difficult incontinence patients, such as those with lower leak point pressures or decreased urethral mobility, according to researchers at Virginia Mason Medical Center in Seattle.

Related Videos

Related Content

Advertisement

January 21st 2025

Incorporating mpMRI in bladder cancer staging may improve time to treatment

Hannah Clarke

The median time to correct treatment was 98 days with initial TURBT vs 53 days with initial mpMRI.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke

Functional success was achieved in 58% of patients at 5-year follow-up.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 18th 2025

Leveraging the full potential of APPs: Mark Edney, MD, on tips for successful collaboration

Mark T. Edney, MD

"There are far more people presenting to us for care than we have people able to provide it. The APPs are going to be a critical part of trying to solve that puzzle," says Mark T. Edney, MD.

January 17th 2025

Enzalutamide included in next round of Medicare drug price negotiations

Hannah Clarke

The 15 drugs identified in this round of negotiations add to the 10 selected in the first round of negotiations that took place in 2023 and 2024.

Related Content

Advertisement

January 21st 2025

Incorporating mpMRI in bladder cancer staging may improve time to treatment

Hannah Clarke

The median time to correct treatment was 98 days with initial TURBT vs 53 days with initial mpMRI.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke

Functional success was achieved in 58% of patients at 5-year follow-up.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 18th 2025

Leveraging the full potential of APPs: Mark Edney, MD, on tips for successful collaboration

Mark T. Edney, MD

"There are far more people presenting to us for care than we have people able to provide it. The APPs are going to be a critical part of trying to solve that puzzle," says Mark T. Edney, MD.

January 17th 2025

Enzalutamide included in next round of Medicare drug price negotiations

Hannah Clarke

The 15 drugs identified in this round of negotiations add to the 10 selected in the first round of negotiations that took place in 2023 and 2024.